Literature DB >> 28900784

Liver involvement in urea cycle disorders: a review of the literature.

Adrien Bigot1,2,3,4, Michel C Tchan5, Benjamin Thoreau6,7,8,9, Hélène Blasco7,8,10,11, François Maillot6,7,8,9.   

Abstract

Urea cycle disorders (UCDs) are inborn errors of metabolism of the nitrogen detoxification pathway and encompass six principal enzymatic deficiencies. The aging of UCD patients leads to a better knowledge of the long-term natural history of the condition and to the reporting of previously unnoticed manifestations. Despite historical evidence of liver involvement in UCDs, little attention has been paid to this organ until recently. Hence, we reviewed the available scientific evidence on acute and chronic liver dysfunction and liver carcinogenesis in UCDs and discuss their pathophysiology. Overall, liver involvement, such as acute liver failure or steatotic-like disease, which may evolve toward cirrhosis, has been reported in all six main UCDs. Excessive glycogen storage is also a prominent histologic feature, and hypoglycemia has been reported in citrin deficiency. Hepatocarcinomas seem frequent in some UCDs, such as in citrin deficiency, and can sometimes occur in non-cirrhotic patients. UCDs may differ in liver involvement according to the enzymatic deficiency. Ornithine transcarbamylase deficiency may be associated more with acute liver failure and argininosuccinic aciduria with chronic liver failure and cirrhosis. Direct toxicity of metabolites, downstream metabolic deficiencies, impaired tricarboxylic acid cycle, oxidative stress, mitochondrial dysfunction, energy deficit, and putative toxicity of therapies combine in various ways to cause the different liver diseases reported.

Entities:  

Mesh:

Year:  2017        PMID: 28900784     DOI: 10.1007/s10545-017-0088-5

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  17 in total

1.  Acute liver dysfunction with delayed peak of serum aminotransferase levels as a presentation of ornithine transcarbamylase deficiency in females.

Authors:  Kathryn Clarkston; Joy Lee; Sarah Donoghue; Heidi Peters; Hernan Eiroa; Amit A Shah; Kathleen Loomes; Jessica Wen; Mark Oliver; Winita Hardikar; Carlos E Prada; Akihiro Asai
Journal:  Am J Med Genet A       Date:  2020-12-24       Impact factor: 2.802

2.  Pyruvate-Carboxylase-Mediated Anaplerosis Promotes Antioxidant Capacity by Sustaining TCA Cycle and Redox Metabolism in Liver.

Authors:  David A Cappel; Stanisław Deja; João A G Duarte; Blanka Kucejova; Melissa Iñigo; Justin A Fletcher; Xiaorong Fu; Eric D Berglund; Tiemin Liu; Joel K Elmquist; Suntrea Hammer; Prashant Mishra; Jeffrey D Browning; Shawn C Burgess
Journal:  Cell Metab       Date:  2019-04-18       Impact factor: 27.287

Review 3.  Urea cycle disorders-update.

Authors:  Shirou Matsumoto; Johannes Häberle; Jun Kido; Hiroshi Mitsubuchi; Fumio Endo; Kimitoshi Nakamura
Journal:  J Hum Genet       Date:  2019-05-20       Impact factor: 3.172

Review 4.  Inborn errors of metabolism in the differential diagnosis of fatty liver disease.

Authors:  Yılmaz Yıldız; Hatice Serap Sivri
Journal:  Turk J Gastroenterol       Date:  2020-01       Impact factor: 1.852

Review 5.  Effects of sulforaphane on brain mitochondria: mechanistic view and future directions.

Authors:  Fernanda Rafaela Jardim; Fhelipe Jolner Souza de Almeida; Matheus Dargesso Luckachaki; Marcos Roberto de Oliveira
Journal:  J Zhejiang Univ Sci B       Date:  2020 Apr.       Impact factor: 3.066

6.  Chronic liver disease and impaired hepatic glycogen metabolism in argininosuccinate lyase deficiency.

Authors:  Lindsay C Burrage; Simran Madan; Xiaohui Li; Saima Ali; Mahmoud Mohammad; Bridget M Stroup; Ming-Ming Jiang; Racel Cela; Terry Bertin; Zixue Jin; Jian Dai; Danielle Guffey; Milton Finegold; Sandesh Nagamani; Charles G Minard; Juan Marini; Prakash Masand; Deborah Schady; Benjamin L Shneider; Daniel H Leung; Deeksha Bali; Brendan Lee
Journal:  JCI Insight       Date:  2020-02-27

7.  Hepatocyte-derived MANF mitigates ethanol-induced liver steatosis in mice via enhancing ASS1 activity and activating AMPK pathway.

Authors:  Han-Yang Xu; Yan-Hong Jiao; Shi-Yu Li; Xu Zhu; Sheng Wang; Yu-Yang Zhang; Yi-Jun Wei; Yu-Jun Shen; Wei Wang; Yu-Xian Shen; Jun-Tang Shao
Journal:  Acta Pharmacol Sin       Date:  2022-06-02       Impact factor: 6.150

8.  Targeting purine synthesis in ASS1-expressing tumors enhances the response to immune checkpoint inhibitors.

Authors:  Rom Keshet; Joo Sang Lee; Lital Adler; Eytan Ruppin; Ayelet Erez; Muhammed Iraqi; Yarden Ariav; Lisha Qiu Jin Lim; Shaul Lerner; Shiran Rabinovich; Roni Oren; Rotem Katzir; Hila Weiss Tishler; Noa Stettner; Omer Goldman; Hadas Landesman; Sivan Galai; Yael Kuperman; Yuri Kuznetsov; Alexander Brandis; Tevi Mehlman; Sergey Malitsky; Maxim Itkin; S Eleonore Koehler; Yongmei Zhao; Keyur Talsania; Tsai-Wei Shen; Nir Peled; Igor Ulitsky; Angel Porgador
Journal:  Nat Cancer       Date:  2020-08-31

9.  Nitrogenous compounds in the saliva and blood of cirrhotic patients: a cross-sectional study.

Authors:  Nathália Tuany Duarte; Jefferson R Tenório; Natália Silva Andrade; Fabiana Martins; Marina Gallottini; Karem L Ortega
Journal:  Clin Oral Investig       Date:  2022-02-28       Impact factor: 3.573

10.  Biomarkers for liver disease in urea cycle disorders.

Authors:  Sandesh C S Nagamani; Saima Ali; Rima Izem; Deborah Schady; Prakash Masand; Benjamin L Shneider; Daniel H Leung; Lindsay C Burrage
Journal:  Mol Genet Metab       Date:  2021-04-08       Impact factor: 4.204

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.